The USAN Council encourages all manufacturers who have discovered or developed a new drug to submit a proposed nonproprietary name (or names) to the secretary of the Council on Drugs, when its preliminary clinical evaluation indicates that more extensive clinical testing is warranted, or sooner if possible. These submissions will be referred to the USAN Council, the joint nomenclature committee of the American Medical Association, American Pharmaceutical Association, and the United States Pharmacopeia, for its consideration. Submission of a nonproprietary name is also desired for new salts of older drugs as well as for nonproprietary names already adopted or recommended by other national or international agencies.
The initial submission of nonproprietary terminology should be accompanied by disclosure of the manufacturer's code number, the chemical name (Chemical Abstracts index names only are to be used) and the structural formula of the compound when these are known or by a description of
Procedures and Principles of the USAN Council. JAMA. 1965;191(12):1019-1021. doi:10.1001/jama.1965.03080120053015